M. Scemama

发表

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Deepak L. Bhatt, R. Diaz, H. White, 2022, The lancet. Diabetes & endocrinology.

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Deepak L. Bhatt, R. Diaz, H. White, 2022, Circulation.

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, British journal of clinical pharmacology.

Lot-to-Lot Consistency of a Combined Hexavalent Diptheria-Tentanus-Acellular-Pertussis, Hepatitis B, Inactivated Polio and Haemophilus b Conjugate Vaccine, Adminstered to Healthy Chilean Infants at 2, 4 and 6 Months of Age

M. Levine, L. Hessel, F. Schödel, 2005, Human vaccines.

Takotsubo cardiomyopathy and anaesthesia.

I. Rouquette, M. Christias, M. Scemama, 2010, British journal of anaesthesia.

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.

S. Daniels, S. Caprio, E. Bruckert, 2020, Journal of clinical lipidology.

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study

S. Daniels, S. Caprio, M. Charng, 2022, Arteriosclerosis, thrombosis, and vascular biology.

[Radiculomyeloencephalitis caused by Angiostrongylus cantonensis in children].

O. Dulac, C. Chiron, M. Scemama, 1988, Archives francaises de pediatrie.

The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension.

A. Morris, J. Reid, R. Donnelly, 1995, British journal of clinical pharmacology.

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

P. López-Jaramillo, R. Diaz, H. White, 2021, Journal of the American College of Cardiology.

[Value of deliberate normovolemic hemodilution associated with a capillary vasoconstrictor, ornipressin, in surgery of the spine].

J. Bernière, M. Scemama, M. Bercovy, 1982, Annales francaises d'anesthesie et de reanimation.

Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome.

Deepak L. Bhatt, R. Diaz, H. White, 2023, The Canadian journal of cardiology.

Dose-effect relationship of rilmenidine after chronic administration

M. Lambert, P. Ambrosi, R. Luccioni, 2004, European Journal of Clinical Pharmacology.

Effect of alirocumab on cataracts in patients with acute coronary syndromes

P. Steg, J. Jukema, G. Schwartz, 2023, BMC Ophthalmology.

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP–IPV–PRP∼T–HBs) combination vaccine

M. Watson, G. Golm, J. Liese, 2007 .

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

L. Milani, B. Nordestgaard, K. Hveem, 2023, Critical care explorations.

Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

R. Pordy, M. Scemama, J. Mcginniss, 2024, Journal of Clinical Lipidology.